Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Prescribing Information: Zepbound (tirzepatide) injection
Common for patients with mild hypertension on monotherapy
Poor glycemic control in the periconception period and in pregnancy has significant maternal and perinatal risks ( As for addressing key questions remaining in regards to this topic we first suggest future studies to more thoroughly report maternal and treatment characteristics including trimester of exposure
The off-label band (BMI 25 to 26.9) Below BMI 27, weight-loss injections arent covered by the MHRA licence
et al., The increasing rate of diabetes in Pakistan: A silent killer (2022) IDF, Prevalence of Diabetes in Pakistan (2024) Jastreboff et al., NEJM, Phase 2 obesity trial of retatrutide (2023) Reuters Next generation Lilly weight-loss drug shows added heart, liver benefits (2024) Investopedia / news20 Eli Lilly shares rise after drug helps patients lose more weight than competitors (2023) Lancet Phase 2 trial on T2DM (via ResearchGate summary) PMC meta-analysis: weight/metabolic outcomes of retatrutide Anti-obesity medication (retatrutide entry) News21 (Axios) Extraordinary promise of retatrutide (2023) USA Today (American Diabetes Association summary) News25 (NY Post) re: Phase 3 status and side effects
